Literature DB >> 10646122

The effect of pregnancy on bone density and bone turnover.

K E Naylor1, P Iqbal, C Fledelius, R B Fraser, R Eastell.   

Abstract

During pregnancy, the mother adapts to meet the calcium demands of the fetus. The effect of this adaptation on the maternal skeleton is not fully understood. Our objectives were to evaluate changes in bone mineral density (BMD) and bone turnover during pregnancy. We studied 16 women longitudinally, with baseline measurements before pregnancy; then at 16, 26, and 36 weeks of pregnancy; and postpartum. We measured total-body BMD and biochemical markers of bone resorption (urinary pyridinium crosslinks and telopeptides of type I collagen) and bone formation (serum bone alkaline phosphatase, propeptides of type I procollagen [PINP] and osteocalcin). We also measured parathyroid hormone (PTH), insulin-like growth factor I (IGF-I), and human placental lactogen. Postpartum, BMD increased in the arms (2.8%, P < 0.01) and legs (1.9%, P < 0.01) but decreased in the pelvis (-3.2%, P < 0.05) and spine (-4.6%, P < 0.01) compared with prepregnancy values. All biochemical markers, with the exception of osteocalcin concentration, increased during pregnancy. The change in IGF-I at 36 weeks was related to the change in biochemical markers (e.g., PINP, r = 0.72, P = 0.002). Pregnancy is a high-bone-turnover state. IGF-I levels may be an important determinant of bone turnover during pregnancy. Elevated bone turnover may explain trabecular bone loss during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646122     DOI: 10.1359/jbmr.2000.15.1.129

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  59 in total

1.  Parity and risk of hip fracture in postmenopausal women.

Authors:  M Kauppi; M Heliövaara; O Impivaara; P Knekt; A Jula
Journal:  Osteoporos Int       Date:  2010-10-06       Impact factor: 4.507

2.  Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health.

Authors:  S R Mastaglia; N P Watman; B Oliveri
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

3.  Bone turnover markers during lactation, postpartum amenorrhea and resumption of menses.

Authors:  D Holmberg-Marttila; A Leino; H Sievänen
Journal:  Osteoporos Int       Date:  2003-02-12       Impact factor: 4.507

Review 4.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

5.  Serum 1,25-dihydroxyvitamin D and calcium intake affect rates of bone calcium deposition during pregnancy and the early postpartum period.

Authors:  Kimberly O O'Brien; Carmen M Donangelo; Lorrene D Ritchie; Ginny Gildengorin; Steve Abrams; Janet C King
Journal:  Am J Clin Nutr       Date:  2012-05-30       Impact factor: 7.045

6.  The Pattern of Gestational Weight Gain is Associated with Changes in Maternal Body Composition and Neonatal Size.

Authors:  Elizabeth M Widen; Pam R Factor-Litvak; Dympna Gallagher; Anne Paxton; Richard N Pierson; Steven B Heymsfield; Sally A Lederman
Journal:  Matern Child Health J       Date:  2015-10

7.  Changes in bone mineral density and body composition during pregnancy and postpartum. A controlled cohort study.

Authors:  U K Møller; S Við Streym; L Mosekilde; L Rejnmark
Journal:  Osteoporos Int       Date:  2011-05-25       Impact factor: 4.507

Review 8.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 9.  Actions of pituitary hormones beyond traditional targets.

Authors:  Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen
Journal:  J Endocrinol       Date:  2018-03-19       Impact factor: 4.286

10.  Osteocalcin, under-carboxylated osteocalcin and osteopontin are not associated with gestational diabetes mellitus but are inversely associated with leptin in non-diabetic women.

Authors:  R Saucedo; G Rico; G Vega; L Basurto; L Cordova; R Galvan; M Hernandez; E Puello; A Zarate
Journal:  J Endocrinol Invest       Date:  2014-12-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.